Ahmed Abdeen Hamed

The paper develops an LLM-driven framework for drug repurposing in ER+ breast cancer, identifying 166 significant drug combinations using pathway analysis and consensus networks.

MechAInistic uses a multi-agent system guided by LLMs to generate auditable hypotheses from genome-scale metabolic models, identifying potential drug targets and metabolic rewiring in disease states.

MarkerScout ranks biomarkers across clinical phases using a disease-agnostic framework with cross-validated F1 scores above 0.99 and direction-aware tiers.